were predictive of cardiovascular mortality in patients with established coronary heart disease (CHD) and were predictive of the progression of vascular disease (2) . Moreover, these associations appeared robust after adjustment for potential confounding influences on both Abeta40 levels and cardiovascular risk, such as age and renal function, and had incremental predictive value for cardiovascular mortality over and above that obtained from the assessment of conventional cardiovascular risk factors alone. They concluded that circulating levels of Abeta40 may help predict which patients with established CHD are at higher risk of cardiovascular mortality and thus may benefit from more intensive conventional CVD risk reduction strategies. They also suggested that these findings may point to novel pathways for CVD development that involve Abeta40, which may point to a novel target for CVD prevention.
Although their study is preliminary and too small to be considered definitive, their hypothesis is certainly worth closer attention. That said, it should be acknowledged that the association between circulating Abeta40 and mortality in patients with CHD could simply reflect imperfect correction for factors that elevate Abeta40 levels, such as impaired renal function, which is itself a potent risk factor for cardiovascular morbidity and mortality. In other words, the mortality associations with Abeta40 levels could simply be indicative of another factor that is influencing both cardiovascular risk and Abeta40 and that Abeta40 is not directly contributing to the CVD risk per se. An alternative view is that they have identified a heretofore unrecognized causal link be- has no relationships relevant to the contents of this paper to disclose. Finally, it is unlikely that Abeta proteins have been preserved through evolution to induce cell injury and more likely that their proinflammatory action is a In conclusion, the study of Stamatelopoulos et al.
(2) highlights a potential link between Abeta and CVD mortality (2) . It is an observation that requires replication but stimulates debate about the normal function of Abeta and its role, if any, in vascular disease.
Is it a biomarker or mediator of chronic subclinical vascular inflammation and/or a poorly studied natural AMP defense against a hitherto unidentified chronic infectious agent implicated in the development of atheromatous disease? Intriguing questions indeed.
